TB-500 + AOD-9604 Stack: Evidence, Mechanism, and What the Research Actually Shows

What TB-500 and AOD-9604 Are (and Are Not)

These two peptides are frequently grouped together in recovery and body-composition stacks, yet their origins and biological targets are quite different. Understanding each individually is necessary before evaluating any rational basis for combining them.

TB-500: The Thymosin Beta-4 Fragment

Thymosin beta-4 (Tβ4) is a 43-amino-acid protein expressed in virtually every human cell type. Its primary roles include G-actin sequestration, cell migration promotion, and anti-inflammatory signaling. The synthetic peptide marketed as TB-500 corresponds to the tetrapeptide region at positions 17-23 (Ac-SDKP in some formulations) or to a longer active fragment, depending on the manufacturer. This fragment retains much of Tβ4's wound-healing and anti-fibrotic activity.

Preclinical research has shown that Tβ4 promotes angiogenesis, reduces apoptosis in cardiomyocytes, and accelerates re-epithelialization of skin wounds. A 2004 paper in the Annals of the New York Academy of Sciences by Malinda et al. Documented Tβ4-accelerated corneal wound healing in animal models [1]. Separately, a study published in Circulation demonstrated that systemic Tβ4 administration after experimental myocardial infarction in rats activated epicardial progenitor cells and reduced scar area [2].

AOD-9604: The Lipolytic HGH Fragment

AOD-9604 is a 16-amino-acid C-terminal fragment of human growth hormone (residues 176-191), with an added tyrosine residue at the N-terminus to improve stability. The fragment was engineered specifically to capture growth hormone's fat-metabolizing properties while avoiding the insulin-desensitizing and IGF-1-stimulating effects associated with full-length GH. Receptor binding studies confirm that AOD-9604 does not activate the GH receptor in the same conformation as intact GH, which explains the absence of IGF-1 elevation in clinical testing [3].

A Phase 2 study of oral AOD-9604 published data showing modest but statistically significant body weight reductions in overweight adults at doses of 1 mg/day over 12 weeks, though Phase 3 trials failed to replicate meaningful clinical benefit at the primary endpoint [4]. The peptide was subsequently designated GRAS (Generally Recognized As Safe) for use in food products in Australia, a designation that should not be conflated with FDA drug approval.

Mechanism Overlap: Where the Two Peptides Converge

The combination's theoretical appeal depends substantially on whether the two peptides act on shared or complementary pathways. The honest answer: overlap exists, but it is limited, and that limited overlap is actually part of the rationale for stacking.

Shared Anti-Inflammatory Signaling

Both peptides appear to reduce pro-inflammatory cytokine activity through distinct upstream mechanisms. TB-500 downregulates NF-kB signaling and decreases TNF-alpha and IL-6 in injured tissue, as documented in a 2012 study examining Tβ4 in a rodent dermal wound model [5]. AOD-9604 has shown beta-3 adrenergic receptor activity in adipocyte studies, and beta-3 agonism is associated with reduced macrophage-derived inflammatory mediators in adipose tissue [6].

These are parallel anti-inflammatory pathways, not the same one. The practical implication: redundant anti-inflammatory coverage across tissue compartments (structural vs. Adipose) rather than synergistic amplification of a single pathway.

Adipose Tissue and Metabolic Crossover

TB-500 has not demonstrated meaningful direct lipolytic activity. AOD-9604 has not demonstrated meaningful tissue-repair activity. This clean separation of primary targets means co-administration is not mechanistically redundant. One peptide addresses connective tissue and vascular repair; the other addresses adipocyte metabolism and fat oxidation.

A small crossover exists in the metabolic domain. Tβ4 influences glucose transporter expression in cardiomyocytes, and some animal data suggest effects on hepatic lipid metabolism [7]. These are secondary effects, not primary mechanisms, and should not be overstated.

No Receptor Competition

Neither peptide occupies the GH receptor with high affinity in the conventional sense, and neither competes for the same binding site. TB-500 works primarily through interaction with G-actin and downstream Akt/PI3K signaling. AOD-9604 binds a discrete region of the GH receptor beta-loop without triggering the full conformational change required for IGF-1 axis activation [3]. There is no known pharmacodynamic antagonism between the two agents.

What the Evidence Actually Shows

This is the section where most competitor articles overstate the data. The TB-500 + AOD-9604 combination has zero published randomized controlled trials. What exists: mechanistic cell studies, animal models, and one class of Phase 2 data for AOD-9604 alone. Practitioners and patients using this stack are doing so in the absence of direct human combination evidence.

Animal Evidence for TB-500

Thymosin beta-4 has the deeper preclinical literature of the two peptides. Key findings include:

• In a 2010 Circulation study (N=not a clinical trial, murine model), systemic Tβ4 given post-myocardial infarction reactivated quiescent epicardial cells and reduced infarct area by approximately 24% compared to vehicle controls [2].
• A rodent tendon-repair study published in the Journal of Orthopaedic Research found Tβ4 treatment accelerated type-I collagen deposition at the injury site by week 4 compared to saline controls [8].
• Anti-fibrotic effects in a liver fibrosis mouse model were documented in 2011, with Tβ4 reducing hydroxyproline content (a fibrosis marker) by roughly 30% [9].

These are animal findings. Extrapolation to human dosing carries significant uncertainty.

Human Evidence for AOD-9604

AOD-9604 has more human trial data than TB-500, though the data is disappointing for the obesity indication that drove its development.

A 24-week Phase 2 randomized trial (NCT not publicly listed; results published by Heffernan et al.) tested oral AOD-9604 at 500 mcg/day, 1 mg/day, and placebo. The 1 mg/day group lost a mean of 2.8 kg more than placebo at week 12, a difference that was statistically significant (P<0.05) but clinically modest [4]. The Phase 3 program did not meet primary endpoints, and commercial development for obesity was discontinued.

No published human data specifically examines injectable AOD-9604 at the doses used in recreational or clinical peptide protocols (typically 250-300 mcg subcutaneously per day). The GRAS designation for the oral form does not validate the injectable route's safety or efficacy.

Evidence Gap Statement

The table below summarizes the evidence tier for each agent and for the combination. Physicians reviewing this content for HealthRX have graded each tier using the Oxford Centre for Evidence-Based Medicine framework:

| Evidence Domain | TB-500 (Tβ4 fragment) | AOD-9604 | TB-500 + AOD-9604 Combined | |---|---|---|---| | RCT in humans | None | Phase 2 (oral, obesity); Phase 3 failed | None | | Controlled animal data | Multiple (cardiac, wound, tendon) | Adipocyte and rodent obesity models | None | | Mechanism characterization | Well-described (Akt/PI3K, actin dynamics) | Partial (beta-3 AR, GH receptor fragment) | Inferred only | | Long-term human safety | Unknown | Limited Phase 2 data (24 weeks, oral) | Unknown | | OCEBM Evidence Grade | 4 (animal/preclinical) | 2b (single Phase 2 RCT; Phase 3 failure) | 5 (expert opinion/mechanism only) |

Any protocol built on this stack is operating at OCEBM Grade 5 for the combination itself.

Dosing Frameworks Referenced in Clinical Practice

Because no approved protocol exists, practitioners who administer these peptides work from manufacturer specifications, Phase 2 dose-finding data (for AOD-9604), and consensus within peptide-focused medical communities. The following represents commonly cited dosing ranges, not HealthRX-endorsed prescribing instructions.

TB-500 Dosing Patterns

TB-500 is typically supplied as a lyophilized powder for reconstitution and subcutaneous injection. Commonly cited loading and maintenance patterns in the literature and clinical peptide communities include:

• Loading phase: 2-2.5 mg subcutaneously twice weekly for 4-6 weeks
• Maintenance phase: 2-2.5 mg subcutaneously once weekly for an additional 4-8 weeks
• Injury-specific acute use: some practitioners front-load at 5 mg/week divided into two doses for the first two weeks following acute musculoskeletal injury

No dose-ranging human study has established an optimal or maximally tolerated dose. The animal cardiac studies used intraperitoneal doses equivalent to roughly 20-50 mcg/kg in rodents, which does not directly translate to human subcutaneous dosing [2].

AOD-9604 Dosing Patterns

Phase 2 oral studies used 1 mg/day. Injectable protocols referenced in clinical peptide communities differ substantially:

• Common injectable range: 250-300 mcg subcutaneously once daily, typically in the morning in a fasted state
• Some practitioners use a 5-day-on, 2-day-off cycling pattern over 12 weeks
• Oral dosing at 500 mcg/day has been studied; sublingual dosing is referenced anecdotally but lacks any pharmacokinetic data

The rationale for morning fasted dosing with AOD-9604 is that beta-3 adrenergic receptor sensitivity in adipocytes is higher in the fasted state and that insulin suppresses lipolytic signaling [6].

Combining the Two: Timing and Administration

When practitioners combine these peptides, the most common approach separates TB-500 injections (twice weekly, larger volume) from AOD-9604 injections (daily, smaller volume at a separate site). There is no pharmacokinetic interaction data to guide this. The separation is precautionary rather than evidence-based.

Rotating injection sites remains standard practice for any subcutaneous peptide protocol. Abdomen and thigh sites are most commonly reported. Bacteriostatic water is the standard reconstitution vehicle for both agents; sterile water can also be used if injections are completed promptly after reconstitution.

Regulatory Status and Safety Considerations

Both peptides are unapproved drugs in the United States. The FDA has not cleared either TB-500 or AOD-9604 for any therapeutic indication in humans. The FDA's definition of a drug under 21 U.S.C. Section 321(g)(1) covers any article intended to affect the structure or function of the body, which means these peptides fall under FDA jurisdiction regardless of how they are labeled or sold [10].

FDA and Compounding Pharmacy Status

The FDA's 2024 guidance on bulk drug substances has created a shifting regulatory environment for peptides at compounding pharmacies. Several peptides previously available through 503A and 503B compounders have been placed on the FDA's category 2 list (substances presenting demonstrable safety concerns), which restricts their use in compounded preparations.

As of early 2025, TB-500 (as thymosin beta-4 or its fragments) and AOD-9604 are not on the FDA's list of bulk substances nominated and approved for compounding, meaning they cannot be legally compounded by registered pharmacies for human use in the United States [11]. Practitioners and patients should verify current status directly with the FDA's official compounding communications, as the regulatory field changes frequently.

Known Adverse Effects

Neither peptide has a well-characterized human adverse-effect profile. Reports from the Phase 2 AOD-9604 oral trials noted mild nausea and transient headache at 1 mg/day with rates only modestly above placebo [4]. Injection-site reactions (redness, mild induration) are the most commonly self-reported side effects with subcutaneously administered peptides.

The theoretical concern with any Tβ4-related peptide is its role in cell migration. Because Tβ4 promotes angiogenesis and cell motility, an unresolved question is whether exogenous administration could accelerate growth of occult neoplasms. No human data confirms this risk, but no adequate long-term human oncology safety study exists either. This gap should inform shared decision-making discussions [1].

Who Might Consider This Stack and Who Should Not

Practitioners who prescribe peptides outside FDA-approved pathways are generally targeting one of two profiles: athletes or active adults seeking accelerated musculoskeletal recovery, and metabolically overweight individuals who have plateaued on other interventions.

The stack's theoretical case is strongest for someone simultaneously pursuing:

1. Repair of a soft-tissue injury (tendon, ligament, or muscle) where TB-500's angiogenic and anti-fibrotic properties may offer benefit
2. Fat-loss optimization where AOD-9604's lipolytic mechanism, while modest in Phase 2 data, may provide additive effect alongside a caloric deficit and resistance training

The stack is least defensible for someone without an active tissue injury who is primarily seeking weight loss. AOD-9604 as a monotherapy produced only 2.8 kg additional weight loss over 12 weeks in a controlled trial, and adding TB-500 does not address the lipolytic mechanism at all [4].

Absolute contraindications to consider include: active malignancy (given Tβ4's cell migration effects), pregnancy (no safety data exists), and any history of hypersensitivity to peptide-based compounds. People under age 18 should not use either peptide.

What Practitioners Should Document

Clinicians who elect to discuss or monitor patients using these peptides off-label should document:

• Baseline inflammatory markers (CRP, ESR) if musculoskeletal repair is the stated goal
• Baseline fasting insulin, fasting glucose, and HOMA-IR if metabolic benefit is the goal
• Baseline and follow-up body composition via DEXA or bioimpedance if body fat change is being tracked
• A signed informed consent acknowledging that both peptides are unapproved and that the combination specifically lacks any human RCT data

The Endocrine Society's position on off-label GH-related peptide use emphasizes that "no peptide hormone or fragment thereof should be used in clinical practice without adequate evidence of safety and efficacy from well-designed clinical trials," a statement applicable to both agents discussed here [12].